NCT06605105View on ClinicalTrials.gov

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

PHASE3RecruitingINTERVENTIONAL

Enrollment

468

Participants

Timeline

Start Date

July 18, 2025

Primary Completion Date

March 15, 2028

Study Completion Date

March 15, 2028

Conditions

Major Depressive Disorder

Interventions

DRUG

CYB003

CYB003 is a deuterated psilocin analog

Trial Locations (2)

30030

RECRUITING

Cenexel iResearcvh Atlanta, LLC, Atlanta

33024

RECRUITING

Research Centers of America, Hollywood

Sponsors

Collaborators (1)

Worldwide Clinical Trials

All Listed Sponsors

collaborator

Worldwide Clinical Trials

OTHER

lead

Cybin IRL Limited

INDUSTRY

NCT06605105 - Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) | Biotech Hunter | Biotech Hunter